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The ability of a cell to undergomitochondrial apoptosis is governed by pro- and
anti-apoptotic members of the BCL-2 protein family. The equilibrium of
pro- versus anti-apoptotic BCL-2 proteins ensures appropriate regulation
of programmed cell death during development and maintains organismal
health. When unbalanced, the BCL-2 family can act as a barrier to apoptosis
and facilitate tumour development and resistance to cancer therapy. Here
we discuss the BCL-2 family, their deregulation in cancer and recent
pharmaceutical developments to target specific members of this family as
cancer therapy.1. Introduction
Apoptosis is a form of regulated cell death that is triggered in response to devel-
opmental cues or cellular stress. This selective cell suicide plays an essential role
in numerous physiological and pathological processes including development,
immunity and disease where the elimination of damaged or superfluous cells
helps to ensure organismal health [1].
There are two apoptotic pathways—the extrinsic pathway (activated by ligand
engagement of cell surface death receptors) and the intrinsic (mitochondrial) path-
way. This review focuses on the BCL-2 familyof proteins that regulate activation of
the intrinsic apoptotic pathway in response to cellular stresses such as DNA
damage, g-irradiation, oncogene activation and growth factor withdrawal.
Recent pharmaceutical advances have allowed the specific targeting of
protein–protein interactions in the BCL-2 (B-cell lymphoma 2) family [2–4].
Early clinical results in haematological cancers show considerable promise.
This review will summarize apoptotic pathway regulation by the BCL-2
family, their perturbation in cancer and utility as therapeutic targets.2. The BCL-2 family
The founder member, BCL-2, was first identified through chromosomal mapping
in follicular lymphoma where constitutive BCL-2 expression is driven from the
immunoglobulin locus by the t[12;18] translocation [5–7]. Unlike the cell
growth and proliferative functions of other known oncoproteins at that time,
BCL-2 was found to facilitate oncogenesis through cell death resistance [8,9]. In
the following years over 15 proteins have been added to this family, each contain-
ing one or more BCL-2 homology (BH) domain and functional studies have
allowed grouping into three classes (figure 1).
A clear division in the family exists betweenmembers that function to prevent
apoptosis (pro-survival or anti-apoptotic) and those that induce apoptosis (pro-
apoptotic). The pro-apoptotic BCL-2 family members can be further divided into
the multi-BH-domain effector proteins (containing BH1, BH2 and BH3 domains)
and BH3-only proteins (only region of homology to BCL-2 is BH3) (figure 1).
Physical interaction between pro-survival and pro-apoptotic family members
can buffer the cell against the onset of mitochondrial-mediated apoptosis.
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Figure 1. The BCL-2 family is composed of pro-survival and pro-apoptotic proteins. BCL-2 family members show sequence homology to BCL-2 in one or more BH
(BCL-2 homology) domain. These proteins can be divided into pro-survival and pro-apoptotic proteins. Within the pro-apoptotic members there is a further subdivision
between the multi-BH domain containing effector proteins and those proteins whose only region of homology to BCL-2 is BH3 (known as BH3-only proteins).
Membrane insertion is mediated by transmembrane domains (TMD) present in pro-survival, effector and some BH3-only proteins (*BIM, BIK and HRK).
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regions together form a hydrophobic pocket that can be filled
by the amphipathic a-helical BH3 domain of pro-apoptotic
BCL-2 proteins [10,11]. The balance of this interaction ensures
appropriate apoptotic regulation in response to development
cues and cellular stresses. In a simple model, when pro-survi-
val proteins predominate, apoptosis is held in check: when
pro-apoptotic proteins predominate, apoptosis is triggered.
However, localization and conformation of BCL-2 proteins is
also important in regulation of activity.mitochondrial outer 
membrane 
permeabilization
apoptosis
substrate cleavage
caspases
BAX/BAK 
oligomerization
apoptosome formation
Figure 2. BCL-2 family interactions regulate mitochondrial outer membrane
permeabilization (MOMP). Interaction between pro-survival and pro-apoptotic
BCL-2 proteins sets a threshold for activation of apoptosis. BCL-2-like pro-
survival proteins inhibit BAX/BAK activation whereas BH3-only proteins
promote BAX/BAK oligomerization. Drugs mimicking the action of BH3-only
proteins indirectly lead to BAX/BAK activation. This allows MOMP,
apoptosome formation and subsequent caspase activation and apoptosis.3. Pro-survival BCL-2 proteins
Pro-survival proteins such as BCL-XL, MCL-1, BFL1 (A1 in
mouse) and BCL-W contain multiple regions of homology to
BCL-2 (figure 2). Each of these proteins is found in many cell
types/tissues and co-expression of multiple pro-survival pro-
teins often occurs. The relative expression levels can vary in a
cell type and developmental manner and are perhaps best
characterized in the haematopoietic system. For example,
dynamic patterns of pro-survival BCL-2 gene expression
occurs during B lymphocyte development with Bclx being
expressed early in B-cell development, Mcl1 and Bcl2 expres-
sion generally increasing with B-cell maturity and A1 levels
peaking in the intermediate stages [12]. In this way, different
pro-survivals play key roles at distinct stages of development.
Levels of pro-survival BCL-2 proteins can also be regu-
lated by protein turnover. BCL-2 and BCL-XL are relatively
stable proteins (e.g. the half-life of BCL-2 approx. 20 h) [13].
By contrast, MCL-1 and A1 protein turnover is constitutive
through polyubiquitination and proteosomal degradation
(reflected in their short half-lives approx. 30 and approx.
15 min, respectively) [14–17]. In this way, levels of MCL-1
and A1 help facilitate dynamic responses to cell death stimuli.
Gene deletion studies have revealed essential and non-
redundant roles of pro-survival BCL-2 proteins in mice. While
embryogenesis proceeds normally in the absence of Bcl2,
deficient mice show postnatal growth retardation, premature
greying, apoptotic involution of spleen/thymus and succumb
to early mortality through polycystic kidney disease with
altered renal cell differentiation and elevated apoptosis [18].Young Bcl2 2/2 mice have normal haematopoietic populations,
but this is not sustained, with notable loss in peripheral
B and T lymphocyte populations [18,19]. These phenotypes
can be reversed by loss of one or two Bim alleles (encoding
a BH3-only pro-apoptotic member of the BCL-2 family),
indicating that sequestration of BIM is the major function of
BCL-2 [20].
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extensive neuronal and haematopoietic apoptosis [21], loss of
Bim can rescue the haematopoetic but not neuronal phenotype
in bclx null embryos [22]. In adult mice, acute deletion of Bclx is
tolerated (animals were followed for 1 month) but still resulted
in severe anaemia, consistent with Bclx being required for reti-
culocyte survival [23]. In contrast to embryogenesis, loss of bim
could not restore erythropoiesis in adults [23].
Deletion studies of A1 had been incomplete until recently
when knockout of all three functional isoforms of A1 in mice
was achieved. Surprisingly, A1 function seems largely redun-
dant, with only minor impact on subsets of cells in the
haematopoietic system [24]. The function of BCL-W also
appears mostly dispensable for normal development and
health, but Bclw-deficient males are infertile due to a defect
in spermatogenesis [25,26].
Across the BCL-2 family the phenotype of the Mcl1
knockout mouse is most severe. Mcl1 deficiency results in
early lethality at pre-implantation stage, but these blastocysts
showed no evidence of increased apoptosis [27], providing a
suggestion of a non-apoptotic role for MCL-1. Conditional
deletion studies in the adult mouse have also revealed an
essential role for MCL-1 in numerous cell types, including
T and B lymphocytes [28], haematopoietic stem cells [29], car-
diomyocytes [30,31], hepatocytes [32], neuronal progenitors
[33] and neutrophils, but not macrophages [34,35], mammary
epithelium or megakaryocytes [36,37].
Interestingly, while MCL-1 deficiency alone in megakar-
yocytes had no impact, when combined with loss of Bclx
this caused embryonic or pre-weaning lethality, which is
also far more dramatic than the impaired platelet shedding
phenotype that is found with loss of just Bclx [36,37]. This
could be rescued by co-deletion of Bax/Bak [37], but clearly
illustrates the co-dependence of certain cell types on multiple
pro-survival proteins. This co-dependence has been shown in
elegant detail in a recent study of immune populations where
multiple pro-survival proteins were targeted by genetic and
pharmacologic methods [38]. Therefore, while gene knockout
studies have given much insight into cell types in which indi-
vidual pro-survival proteins have a dominant role, there has
probably been an underestimation of the extent of their con-
tribution to cell survival in many other cell types. Indeed, the
sum effect of all pro-survival proteins present may be more
important for survival than expression levels of an individual
protein. This is an important consideration for therapeutic
targeting of pro-survival BCL-2 proteins and minimization
of damage to normal tissues.4. Pro-apoptotic BCL-2 members
Pro-apoptotic BCL-2 proteins fall into two sub-classes
(figure 2). BH3-only proteins such as BIM, BAD, BID,
NOXA, PUMA, BMF, HRK and BIK only show homology to
the BH3 domain of BCL-2. The effector proteins BAX, BAK
and BOK contain multiple BH domains and structural studies
of BAX revealed that effector protein three-dimensional confor-
mation is similar to that of pro-survival BCL-2 proteins [39].
Like the pro-survival BCL-2 proteins, multiple pro-apoptotic
proteins are found expressed in cells at the same time.
Upregulation of BH3-only proteins can occur at transcrip-
tional/post-translational levels in response to stress to trigger
cell death. For example, Puma and Noxa are transcriptionaltargets of the p53 tumour suppressor and their expression
is increased in response to cytotoxic stimuli that activate
p53, although PUMA is also important in response to
p53-independent apoptotic stimuli [40]. BH3-only proteins
can also be regulated by post-translational modification.
Phosphorylation of BAD leads to sequestration by 14-3-3
proteins in the cytosol where it cannot exert pro-apoptotic
functions [41]. Other mechanisms of activation exist such as
altered cellular localization. Full-length BID is located in the
cytosol but upon cleavage by caspase 8 (downstream of
death-receptor signalling in the extrinsic apoptotic pathway)
a truncated product is formed (tBID) which is capable of
locating to the mitochondria and activating apoptosis [42].
BAX and BAK contain membrane anchoring C-terminal
tails and while BAK is constitutively bound to the outer mito-
chondrial membrane, in healthy cells BAX appears cytosolic
[43]. However, BAX and (to a lesser degree) BAK are actually
in a dynamic equilibrium between cytosol and membranes,
and are constitutively retrotranslocated to the cytosol by
pro-survival BCL-2 proteins [44–46]. In the absence of any
other BCL-2 proteins BAX becomes membrane localized,
like BAK [45].
The mechanism of activation of BAX/BAK by BH3-only
proteins has been the subject of intense debate. Evidence
exists to suggest that some BH3-only proteins are ‘activators’:
in this model BIM, tBID and PUMA, can directly interact
with BAX/BAK to trigger their conformational change
[47,48]. The function of the other BH3-only proteins in this
model is as ‘sensitizers’, whose binding to BCL2-like pro-survi-
val proteins frees up ‘activator’ BH3-only proteins [47,48]. An
alternative, ‘indirect’ model has also been proposed whereby
pro-survival BCL-2 proteins exert their function through
direct interaction with BAX/BAK and BH3-only proteins act
to sequester pro-survival proteins away from BAX/BAK.
Such interactions do not always depend on BH3 domains as
transmembrane domain (TMD) dimerization also occurs in
the outer mitochondrial membrane. This has been observed
in non-apoptotic cells and could indicate competition between
the TMDs of pro-survival proteins such as BCL-2 and BCL-XL
to prevent BAX/BAK homo-oligomerization [49].
Recently, genome editing was used to disrupt all known
BH3-only proteins (eight in total) in HCT116 cells rendering
these cells resistant to stress-induced apoptosis [50]. Interest-
ingly, treatments that downregulate/target MCL-1- and
BCL-XL-induced apoptosis with equivalent kinetics to those
seen in cells proficient for BH3-only proteins revealing that
known BH3-only proteins are not required for BAX/BAK acti-
vation [50]. Instead, association with the mitochondrial outer
membrane is sufficient to drive homo-oligomerization of
BAX/BAK in the absence of pro-survival BCL-2 proteins [50].
Regardless of which model is active in a particular cell type/
situation, the outcome of a relative increase in the levels of
pro- versus anti-apoptotic BCL-2 proteins is the same and the
C-termini of BAX/BAK undergo conformational change that
allows dimerization [51,52]. Reciprocal interaction between
the BH3 domain of one molecule and the hydrophobic groove
on another results in symmetrical homodimers (although het-
erodimers of BAX/BAK can also form in this manner) and
linkage of these leads to higher-order oligomerization [53,54].
These oligomers delineate arcs, lines or ring-like structures in
the outer mitochondrial membrane [55,56]. This mitochondrial
outer membrane permeabilization (MOMP) allows release of
soluble proteins from the mitochondrial inner membrane
NOXA
BAD BCLXL
BCLW
BFL/A1
MCL-1
BCL-2
BIM
PUMA
BID
Figure 3. Specific interactions of BH3-only with pro-survival proteins. Some
BH3-only proteins (BIM, PUMA and BID) are promiscuous and can bind all
pro-survival BCL-2 proteins, whereas others (BAD and NOXA) show a more
restricted binding pattern.
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protease activating factor 1), promoting its oligomerization and
binding to pro-caspase 9—forming a complex termed the
apoptosome. At the apoptosome, pro-caspase-9 is activated via
dimerization,which in turn cleaves and activates the executioner
caspases-3 and -7 to drive mass proteolysis that leads to DNA
fragmentation, chromatin condensation and the dismantling of
the cell. It is important to note that the mitochondrial pathway
also contributes to death-receptor-mediated apoptosis through
caspase 8 cleavage of BID, indeed BAX/BAK are required in
many circumstances for receptor-mediated apoptosis [57,58].
In vivo analysis suggests the function of BAX and BAK is
largely redundant in physiological settings; only a minority of
double knockout mice survive to adulthood [59], but one copy
of either is enough to allownormal development. In the absence
of BAX/BAK apoptosis is impaired in response to almost all
stimuli showing their requirement for the initiation of MOMP
[60]. Less well studied, BOK is an additional multi-domain
pro-apoptotic BCL-2 protein that was identified through its
interaction with MCL-1 [61], although subsequent studies
have suggested that BOK does not interact with pro-survival
BCL-2 proteins [62,63]. BOK transcripts are present in many
tissues inmice [64] but the protein is short-lived due to turnover
by ubiquitylation and endoplasmic reticulum-associated
degradation mediated by the proteasome [63].
BOK shows strong homology to BAX and BAK, and its role
in apoptotic regulation has recently been extensively investi-
gated. BOK deficient mice appear normal [64], but enforced
BOK expression can drive apoptosis in a range of cell types
and there is debate over whether this requires BAX/BAK
[62–67]. EndogenousBOKis foundpredominantly in themem-
branes of the Golgi apparatus and endoplasmic reticulum (ER)
and a function in ER stress response has been suggested [62,65].
More recently, the ability of proteasome inhibitors to induce
apoptosis in BAX/BAK-deficient MEF or HCT116 cells was
shown to require BOK expression but this was independent of
pro-survival BCL-2 family proteins [63]. For now, the role of
BOK certainly seems unique and requires further investigation.5. Favoured interactions
As discussed above, a level of specificity is granted by differen-
tial expression pattern, cellular localization, post-translational
activation and turnover of BCL-2 family proteins. A further
levelof complexitywas revealedbybiochemical andcell biology
studies that showed differential binding affinities of particular
BH3-only proteins for pro-survivals [68,69]. While BH3-only
proteins such as BIM, PUMA and tBID bind with high affinity
to all pro-survival proteins, others are more selective in their
interaction. For example, BAD preferentially interacts with
BCL2, BCL-XL and BCL-W while NOXA showing a reciprocal
interaction preference for onlyMCL-1 andA1 (figure 3). Further
complexity is added bypreference of BH3-only proteins for acti-
vation of BAX or BAK. While BIM and BID bind the same
repertoire of pro-survival proteins (figure 3), preference of BID
to mediate apoptosis through BAK has been shown [70,71],
whereas BIM preference for BAX [70], or no preference [71],
has been observed. Domain swap experiments have revealed
that these effects are determined by the BH3 sequence of the
BH3-only proteins and are dependent on cell type [71].
An additional layer of complexity is added with specificity
in pro-survival proteins for BAK versus BAX activation.MCL-1and BCL-XL constrain BAK, but BCL-2 does not [72], and it is
the BH3 domain of BAK that determines these associations [71].5.1. Increased pro-survival BCL-2 proteins in cancer
Evasion of apoptosis can aid oncogenic transformation at mul-
tiple stages through facilitating sustained tumour growth,
survival during metastatic process and resistance to therapy.
Therefore, it is not surprising that increased expression of pro-
survival BCL-2 proteins is found in many cancer types. This
upregulation canoccur throughavarietyofmechanisms includ-
ing chromosomal translocation, gene amplification, increased
gene expression/translation or protein stability with various
mechanisms and alternative pro-survival BCL-2 protein
increases seeming more prominent in particular cancers.
Besides the Bcl2 t(12;18) translocation, first found in
follicular lymphoma (and subsequently in diffuse large-cell
lymphomas [73]), translocation of BCL-2 family genes is not
common across different cancer types nor does it seem to
occur to other pro-survival members. Interestingly, t(14;18)
translocation of Bcl2 has also been found in peripheral blood
lymphocytes from healthy individuals [74] and modelling of
this translocation in B cells of mice is only weakly tumorigenic
[75]. Together, these data suggest that this translocation is not
overtly oncogenic.
Gene copy number increases in pro-survival BCL-2
members in cancer are more widespread than translocation.
Transgenic modelling of increases in pro-survival proteins has
mostly been limited to the haematopoietic systems where
elevation of Bcl2,Mcl1 or Bclx predisposes to lymphoma devel-
opment, albeit with long latency and incomplete penetrance.
Amplification of MCL1 and BCL2L1 (encodes BCL-XL) were
found to be among the most frequent chromosomal gains in a
study of over 3000 samples representing 26 tumour types
[76]. It is interesting that these amplifications were prominent
outside of haematopoietic cancers, which have been the tra-
ditional niche for studies on tumorigenic roles of the BCL-2
members. Indeed, analysis of The Cancer Genome Atlas
(TCGA) data through cBioportal [77] confirms the prevalence
of MCL1, and to a lesser extent BCL2L1, amplification in
many solid cancers (figure 4). Again, there seems specificity
between family members as BCL2, BCL2A1 (BFL) and BCL2L2
(BCL-W) amplification are much rarer events. Consistent with
a pro-tumour role, mutation or deletion of pro-survival BCL2
proteins was also infrequent (figure 4). While pro-survival
BCL-2 expression on its own is mildly oncogenic, acquisition
of additional genetic hits is clearly required for tumour for-
mation. Co-amplification of MYC with MCL-1 or BCLX is
0 5 10 15 20
% occurrence
amplification
deletion
mutation
AML
bladder
breast
GBM
HNSCC
ccRCC
lung
thyroid
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uterine
BCL2
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Figure 4. Frequency of genomic alteration of pro-survival BCL-2 proteins in
cancer. Frequency of amplification (circle), mutation (triangle) or deletion
(square) of pro-survival BCL-2 members in a range of cancers. Data mined
from TCGA studies through cBioportal [77]. BCL-2 (black), BCL-XL (BCL2L1
blue), MCL-1 (red), BFL (BCL2A1 grey), BCL-W (BCL2L2 purple). AML,
acute myeloid leukaemia [78], 173 cases. Bladder, urothelial carcinoma
nature (TCGA provisional), 408 cases. Breast, invasive carcinoma (TCGA provi-
sional), 1100 cases. GBM, glioblastoma [79], 166 cases. HNSCC, head and
neck squamous cell carcinoma (TCGA provisional), 522 cases. ccRCC, kidney
renal clear cell carcinoma [80], 534 cases. Lung adenocarcinoma (TCGA
provisional), 517 cases. Thyroid, papillary thyroid carcinoma [81], 509
cases. Stomach adenocarcinoma (TCGA provisional), 415 cases. Uterine,
corpus endometrial carcinoma [82], 177 cases.
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increased BCL-2-like proteins, and MYC is a potent oncogenic
combination [83–87].
Increased transcription of pro-survival proteins can also
elevate their expression in cancer and increased transcrip-
tion/translation seems important for regulation of MCL-1
levels. For example, in chronic lymphocytic leukaemia
(CLL) c-ABL has been shown to drive high MCL-1 mRNA
and protein expression through STAT3/NF-kB [88]. Simila-
rly, in a mouse model of B-cell acute lymphoblastic
leukaemia (B-ALL) the BCR-ABL oncoprotein was shown to
drive high levels of MCL-1 expression that was essential for
leukemogenesis [89].
Increased protein translation impacts on MCL-1 and BCL-
XL levels and MCL-1 has been identified as a downstream
mediator of the oncogenic effect of the translation initiation
factor eIF4e [90]. Disruption of pathways regulating MCL-1
protein stability also occurs in cancer (e.g. loss or mutation
of FBW7 inhibits MCL-1 degradation and is associated
with tumorigenesis and resistance to chemotherapy [91,92]).
Therefore, in addition to genetic alterations in BCL-2 family
members, activation of oncogenic signalling pathways can
also increase pro-survival protein levels.
It is important to consider that the observation of high
levels of pro-survival BCL-2 proteins in cancer need not necess-
arily indicate strong apoptotic resistance. Elevation of BCL-2actually sensitizes to apoptosis induced by the BCL-2/BCL-
XL/BCL-W targeting drug ABT-737 through release of high
levels of BIM that have been harboured in BIM/BCL-2 com-
plexes [93]. In this way, a cell can be thought of as primed for
death, close to the threshold required for apoptosis induction
and measurement of the level of mitochondrial priming in
cells can be used to predict response to chemotherapy [94,95].
Alterations in pro-survival BCL2 proteins might have
importance beyond cancer genesis as high levels of MCL-1
expression at diagnosis correlate with poor prognosis in breast
cancer [96], and MCL-1 amplification is prominent in treatment-
resistant breast cancers [97], suggesting that this may be a
source of innate and acquired resistance to cancer therapy.
Such associations do not hold true for pro-survival BCL-2-like
proteins in general and high levels of BCL-2 are actually
associated with good prognosis in breast cancer [98–101].
5.2. Decreased pro-apoptotic BCL-2 proteins in cancer
Decreased expression of pro-apoptotic BCL-2 proteins has the
same functional outcome as increased pro-survival expression
in cancer. Gene deletion studies in mice do not reveal a strong
oncogenic impact of decreased BH3-only protein expression.
With the exception of BAD knockout mice, which succumb to
late onset lymphoma [102], deficiency in individual BH3-only
proteins does not predispose mice to tumour development
[103]. Functional redundancy between BH3-only proteins
could account for this, however, compounddeletion ofmultiple
BH3-only proteins is still only weakly tumour promoting with
autoimmunity contributing to morbidity [104].
Similar to over-expression of pro-survival BCL2-like pro-
teins, loss of BH3-only proteins is not overtly oncogenic but
can dramatically accelerate lymphoma development in the con-
text of elevated MYC. BIM seems most potent in this context,
with deletion of even a single allele of BIM having dramatic
effects [105].
Cancer therapeutics engaging the p53 response would be
predicted to upregulate PUMA and NOXA and resistance
to apoptosis could be mediated by their downregulation.
Indeed, deletion of the gene encoding PUMA (Bbc3) occurs in
a range of cancer types [76] and othermechanisms can decrease
PUMA expression such as promoter methylation [106].
5.3. Altered expression of effector proteins
Elimination or downregulation of apoptotic effector proteins
such as BAX/BAK is a potent way to disable mitochondrial-
mediated apoptosis in cell culture systems. As the function of
BAX and BAK are largely redundant, with one copy of either
allowing normal development, abrogation of their activity
would require loss of all four alleles. There is limited evidence
that this occurs in cancer and BAX/BAK levels naturally
decline with age in mice and humans [107]. It is important to
note that localization and conformation may be even more
important than absolute levels of BAX/BAK. For example, in
acute myeloid leukaemia (AML) mitochondrial localized
BAX is associated with both increased apoptotic sensitivity
and improved patient prognosis [108]. Gene deletion studies
in mice do not suggest a tumour suppressive role for BAX or
BAK when knocked out individually (presumably due to
their redundant roles) and double knockout results in perinatal
lethality [59,109]. Using chimeric mice Bax/Bak deletion in
the haematopoietic compartment drives fatal autoimmune
Navitoclax
(ABT263)
Venetoclax
(ABT-199)
BCL-XL
BCL-W
BFL/A1
MCL-1
BCL-2
AMG176
S64315/MIK665
Figure 5. Selectivity of BH3-mimetic drugs under clinical investigation. Drugs
specifically targeting BCL-2 (Venetoclax/ABT-199), BCL-2, BCL-XL and BCL-W
(Navitoclax/ABT263) or MCL-1 (AMG176, S64315/MIK665) are now in clinical
trial/use.
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meric mice with Bax/Bak [111] deficient haematopoietic
systems may mask tumour development. Targeted deletion
mouse studies can avoid these autoimmune complications
and in this setting loss of BAX/BAK in the brain and testicles
results in tumours [112].
It seems pertinent loss ofBok is a relatively frequent event in
a range of cancers [76] and gene silencing may result in loss of
BOK protein in additional cases [111]. BOK is downregulated
in non-small cell lung cancer (NSCLC) and high BOK is associ-
ated with good prognosis in lymph-node positive patients
[111]. Interestingly, the tumour suppressive effect of BOK in
NSCLC does not seem to be through apoptotic regulation
and is instead through antagonism of TGF-b2 mediated epi-
thelial to mesenchymal transition (EMT) and cell migration
[111]. Unlike so many other BCL-2 proteins, Bok loss failed to
reveal a tumour suppressive role the Eu-Myc mouse model
[64], a system that is a sensitive read-out for altered apoptosis,
although factors such as cooperating second hits, timing of
Bok loss and cell type specificity could all be involved in a
BOK effect. Compound knockout of Bax/Bak/Bok in the
haematopoietic system also results in autoimmune disease
rather than tumourigenesis [113]. More recently, in a chemical
(DEN)-induced model of liver carcinogenesis, loss of BOK
has been shown to protect against cancer. In this model,
cancer can be promoted by death of hepatocytes, supporting
compensatory proliferation with associated mutagenesis, in
surrounding tissue that ultimately leads to live cancer [114].
Interestingly, deletion of BOK inhibited the ER-stress response
and induction of pro-apoptotic BH3-only proteins BIM and
PUMA, placing BOK’s tumour promoting role upstream of
MOMP [114]. Secondly, BOK was also shown to have an
additional growth-promoting effect, though the mechanisms
underlying this remain unclear it would also be expected to
be pro-tumourigenic [114].
5.4. Pharmaceutical intervention to reset the balance
As the balance of BCL-2 proteins can act as a trigger for apop-
tosis, mechanisms to alter their expression or interactionwould
be expected to have clinical use. Indeed conventional anti-
cancer therapies can act through disruption of the BCL-2
family. For example, DNA damaging agents such as etoposide
or daunorubicin activate the p53 tumour suppressor transcrip-
tion factorwhose targets include PUMAandNOXA.However,
the presence of elevated pro-survival BCL-2 proteins can act as
a barrier to apoptosis even upon upregulation of BH3-only
proteins. Neutralization of pro-survival proteins would re-
sensitize to BH3-only upregulation and could even have the
potential to trigger apoptosis alone.
Interest in the development of inhibitors of pro-survival
BCL-2 proteins has come to fruition over the past decade
following the identification of small molecule inhibitors
capable of occupying the hydrophobic pocket on pro-survival
proteins. The first of these BH3 mimetic drugs, ABT-737, was
developed through NMR-based fragment screening. ABT-737
mimics the BH3-domain of pro-apoptotic BAD and interacts
with BCL-2, BCL-XL and BCL-W (figure 5), displacing BH3-
only proteins to trigger apoptosis in cell lines and restrict
tumour growth in xenograft models [2]. Derivation of an
orally available analogue (ABT 263/Navitoclax) allowed
clinical testing [115]. On-target toxicity of Navitoclax was
observed with dose-limiting thrombocytopenia occurringdue to platelet dependence on BCL-XL [116,117]. This can be
managed in the clinic and preclinical models have supported
the use of Navitoclax in clinical trials as a combination therapy
in a range of (predominantly solid) tumour types [118,119]
(clinicaltrials.gov).
Further development has led to additional BH3 mimetics
with increased specificity for individual BCL-2 proteins. The
success of this approach has been shown with the BCL-2
specific BH3 mimetic ABT-199 (Venetoclax), which obtained
breakthrough FDA status for use in relapsed/refractory CLL.
In this disease single-agent efficacy was seen with partial
response in 79% and complete response in 20% of patients
[120]. Evenmore impressive resultswere seenwhenVenetoclax
was used in combination with rituximab-complete response
occurred in 51% of patients with disease-free status occurring
for up to 2 years after completion of therapy [121]. Encouraging
(but more modest) effects are seen in non-Hodgkin lympho-
mas, acute myeloid leukaemia and multiple myeloma as a
single agent [122–124] or combination therapy [125]. While
much is understood of the role of the BCL-2 family in cancers
of the blood, the case for targeting these proteins in solid
tumours, most probably in conjunction with conventional
therapies, is compelling. Translocation or amplification of
BCL2 itself is rarely seen in solid tumours but dependence on
BCL2 has been shown in small cell lung cancer (SCLC) [126].
Efficacy of Venetoclax when used as a combination therapy
has been shown in preclinical models of breast cancer [127]
and Venetoclax is now in clinical trials in combination with
tamoxifen in breast cancer (ISRCTN98335443).
Resistance to BCL-2 and BCL-2/BCL-XL targeting BH3
mimetics has been observed, and in vitro studies indicate that
ABT-737 treatment can increase MCL-1 levels and MCL-1
expression promotes resistance to ABT737 in vitro and in vivo
[128–130]. MCL-1 has been associated with resistance to
cancer therapy for some time [131,132], and interest has intensi-
fied in the development of drugs that specifically target MCL-1.
A number ofMCL-1 inhibitors have beenmooted but until very
recently compounds with clear specificity and on-target effect
were lacking [133]. The tide has turned and a number of
robust BH3 mimetic drugs targeting MCL-1 are now available;
Abbvie’s A1210477 potently inhibits MCL-1 in vitro to restrict
growth of diverse cancer cell lines [134,135], UMI-77 inhibits
pancreatic and breast cancer cell line growth in vitro and
in vivo [96,136], and the Servier compound S63845 seems
particularly potent, with on-target single agent killing of
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combination with conventional cancer therapy in xenograft
models of breast cancer [137]. The potential for MCL-1 specific
BH3-mimetics in the clinic is now being tested with the Novar-
tis/Servier drug S64315/MIK665 and Amgen AMG176 in
phase I clinical trials for haematopoietic cancers/myelodysplas-
tic syndrome (NCT02992483, NCT02979366, NCT02675452).
Taking advantage of the short half-life of MCL-1 protein, a
number of other approaches can be taken to decrease MCL-1
levels. This includes inhibition of transcription through CDK
inhibition [138] or targeting translation through mTOR
inhibition [139]. Beyond targeting anti-apoptotic BCL-2 pro-
teins, increasing interest has centred on developing drugs that
directly activate BAX and BAK in order to kill tumour cells
[140,141]. Along these lines, a recent study has shown that a
BAX-activating molecule, BTSA1, shows potent anti-tumour
effects on human acute myeloid leukaemia (AML) xenografts
in the absence of toxicity [142].6. Inhibiting BCL-2 proteins in cancer
prophylaxis
It is conceivable that targeting the pro-survival BCL-2 proteins
could help eliminate pre-cancerous lesions or early-stage
tumours. Indeed, ABT737 can act as an anti-cancer prophylac-
tic in the Em-MYC mouse model of B-cell lymphoma, which
has been shown to be dependent on BCL-XL [143]. Evidence
for applicability beyond MYC-driven lymphoma is limited
and in p53 null mice (which predominantly succumb to
thymic lymphoma) prophylactic treatment with ABT737
had no impact on tumorigenesis [144]. When low-dose g-
irradiation was added to this experimental protocol to mimic
environmental factors that could induce additional mutations
prophylactic ABT737 treatment was shown to delay lym-
phoma onset in p53 null mice, but this reduction in thymic
lymphoma was accompanied by increased incidence of sar-
coma, and while significant, the difference in survival
outcome afforded by prophylactic ABT 737 treatment was
minimal [144].
Confounding factors include the altered activity of cells
that have failed to be eliminated by targeting pro-survivalBCL2 proteins. For example, the spontaneous apoptosis
induced by targeted deletion of mcl1 in hepatocytes results in
severe liver damage and increased proliferation that actually
results in hepatocellular carcinoma (HCC) [145]. Such effects
have also been shown in models of g-irradiation induced
thymic lymphoma where deletion of puma or over-expression
of Bcl2 (normally considered as pro-cancer events) actually
protects against tumour development [146]. In this scenario,
g-irradiation no longer causes depletion of bonemarrow leuco-
cytes meaning that there is no niche for the proliferation of
stem/progenitor cells carrying damaged DNA that normally
give rise to the thymic lymphomas in this model [146,147].
There are further indications that inhibiting the pro-survivals
may not always have anti-cancer impact, in settings where
ABT737 fails to induce apoptosis detrimental side effects can
occur through activation of CAD and genome instability
[148]. It remains to be seen whether these concerns hold true
in the clinic.
In the decades following the discovery of BCL-2 (and
related family members) a vast quantity of research has unra-
velled their role in regulating apoptosis. The functional
division of this family into pro- and anti-apoptotic members
and the elucidation of their structures and mechanism of inter-
action has allowed the pharmaceutical development of
molecules to specifically inhibit these protein–protein inter-
actions and reinstate apoptosis. Available data from clinical
trials suggests good efficacy of BH3-mimetics targeting
BCL-2 in some types of blood cancer. Deregulation of BCL-2
proteins is now recognized as a frequent event in many types
of cancer and it seems likely that targeting pro-survival
BCL-2 proteins will form a valuable adjunct to current cancer
therapies. Restoration of apoptosis offers the potential to elim-
inate cancer cells at all stages of pathology and as BH3-mimetic
drugs make their way into the clinic they could make dramatic
improvements in survival outcome in cancer.Data accessibility. This article has no additional data.
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